STOCK TITAN

Scholar Rock Holding Corporation (SRRK) Financials

SRRK
FY2025 annual
Revenue $0 YoY not available
Net Income -$378.0M -53.7% YoY
EPS (Diluted) -$3.29 -33.2% YoY
Free Cash Flow -$300.6M -49.5% YoY
Market Cap $6.7B as of Sep 11, 2026
Price / Sales n/m revenue is not positive, FY2025
Price / Earnings n/m net loss, so no earnings multiple, FY2025
Price / Book 26.6x on $253.8M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 11, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the SRRK SEC filings page.

Scholar Rock Holding Corporation (SRRK) reported $0 in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI SRRK FY2025

The dominant mechanic is externally funded development: rising operating costs are being financed outside operations.

In FY2024, earnings and cash conversion moved together: net loss was -$246M while operating cash flow was -$201M, so the reported loss largely represented cash consumption rather than a large working-capital timing gap. With capital expenditures only $98K, the near equality points to operating development spending, not heavy physical reinvestment, as the main cash burden.

The cost base is accelerating: FY2024 R&D reached $185M from $122M in FY2023, while SG&A also expanded; that combination points to broader corporate and development spending rather than a one-line cost spike.

Liquidity is high on the reported balance sheet, with a current ratio of 9.6x, but funding is external: financing cash flow supplied $353M in FY2024 while operating cash flow remained negative. The supplied liquidity measure equaled 14.7 months of the latest annual operating outflow, a snapshot of funding capacity rather than operating self-sufficiency.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

Scholar Rock Holding Corporation does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Safe
18.83

Scholar Rock Holding Corporation scores 18.83, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($6.7B) relative to total liabilities ($158.8M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
1/7

Scholar Rock Holding Corporation passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing
N/A

Scholar Rock Holding Corporation reported a net loss of $378.0M while operations used $300.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

Scholar Rock Holding Corporation reported an operating loss of $384.6M against $6.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA
-$108.6M
YoY+2.8%
QoQ-6.8%

Scholar Rock Holding Corporation's EBITDA was -$108.6M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 2.8% from the same quarter a year earlier. Against the prior quarter it is down 6.8%.

Net Income
-$109.9M
YoY+0.1%
QoQ-4.2%

Scholar Rock Holding Corporation reported -$109.9M in net income in Q2 2026. This represents an increase of 0.1% from the same quarter a year earlier. Against the prior quarter it is down 4.2%.

EPS (Diluted)
-$0.84
YoY+14.3%
QoQ-1.2%

Scholar Rock Holding Corporation earned -$0.84 per diluted share (EPS) in Q2 2026. This represents an increase of 14.3% from the same quarter a year earlier. Against the prior quarter it is down 1.2%.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow
-$70.3M
YoY+8.9%
QoQ+14.4%

Scholar Rock Holding Corporation recorded an outflow of $70.3M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 8.9% from the same quarter a year earlier. Against the prior quarter it is up 14.4%.

Cash & Debt
$437.1M
YoY+185.8%
QoQ+1.5%
5Y CAGR+16.1%

Scholar Rock Holding Corporation held $437.1M in cash against $196.2M in long-term debt as of Q2 2026.

Shares Outstanding
122M
YoY+26.7%
QoQ+1.6%
5Y CAGR+28.7%

Scholar Rock Holding Corporation had 122M shares outstanding in Q2 2026. This represents an increase of 26.7% from the same quarter a year earlier. Against the prior quarter it is up 1.6%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity
-43.3%
YoY+3.9pp
QoQ-5.1pp

Scholar Rock Holding Corporation's ROE was -43.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 3.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 5.1 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending
$58.2M
YoY-6.7%
QoQ+12.4%

Scholar Rock Holding Corporation invested $58.2M in research and development in Q2 2026. This represents a decrease of 6.7% from the same quarter a year earlier. Against the prior quarter it is up 12.4%.

Capital Expenditures
$1K
YoY-99.5%
QoQ-98.5%
5Y CAGR-74.8%

Scholar Rock Holding Corporation invested $1K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 99.5% from the same quarter a year earlier. Against the prior quarter it is down 98.5%.

Share Buybacks

Not reported for Q2 2026.

SRRK Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SRRK quarterly income statement
MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-Q
RevenueN/A$0N/AN/AN/AN/AN/AN/A
R&D Expenses$58.2M-6.7%$51.8M+6.4%N/A$50.5M+3.6%$62.4M+47.3%$48.7M+13.0%N/A$48.7M+60.6%
SG&A Expenses$50.7M+1.9%$50.2M+76.7%N/A$53.1M+230.4%$49.7M+190.3%$28.4M+85.4%N/A$16.1M+20.4%
Operating Income-$108.9M+2.9%-$102.0M-32.3%N/A-$103.5M-59.8%-$112.1M-88.4%-$77.1M-32.0%N/A-$64.8M-48.3%
EBITDA-$108.6M+2.8%-$101.7M-32.6%N/A-$103.1M-60.3%-$111.7M-89.3%-$76.7M-32.6%N/A-$64.3M-49.7%
Interest Expense$4.5M+274.6%$2.3M+26.6%N/A$1.3M-23.5%$1.2M-29.7%$1.8MN/A$1.7M
Net Income-$109.9M+0.1%-$105.5M-41.2%N/A-$102.2M-58.5%-$110.0M-88.1%-$74.7M-31.4%N/A-$64.5M-52.2%
EPS (Basic)-$0.84+14.3%-$0.83-23.9%-$0.75-23.0%-$0.90-36.4%-$0.98-63.3%-$0.67-13.6%-$0.61-22.0%-$0.66-24.5%
EPS (Diluted)-$0.84+14.3%-$0.83-23.9%-$0.75-23.0%-$0.90-36.4%-$0.98-63.3%-$0.67-13.6%-$0.61-22.0%-$0.66-24.5%
Diluted Shares (Avg)131M+15.9%127M+13.8%N/A114M+17.2%113M+16.4%112M+16.6%N/A97M+20.4%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Income Tax.

SRRK Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SRRK quarterly balance sheet
MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-Q
Total Assets$523.5M+54.0%$535.3M+31.3%$404.3M-14.9%$411.7M+129.8%$340.0M+49.9%$407.6M+52.5%$474.9M+52.7%$179.1M-28.5%
Current Assets$507.2M+58.9%$515.3M+33.8%$385.1M-14.6%$390.7M+155.5%$319.1M+60.3%$385.2M+56.0%$451.2M+56.5%$152.9M-33.1%
Cash & Equivalents$437.1M+185.8%$430.5M+212.2%$323.5M+81.9%$286.8M+275.4%$152.9M+63.8%$137.9M+50.0%$177.9M+74.6%$76.4M+13.0%
Short-Term Investments$55.0M-61.3%$49.4M-78.2%$44.0M-83.0%$82.9M+32.2%$142.1M+46.3%$226.4M+54.6%$259.4M+45.7%$62.7M-58.5%
Long-Term Investments$0$0$0$0$0$0$0$0
Total Liabilities$269.8M+152.7%$259.2M+172.3%$158.8M+49.4%$166.7M+66.8%$106.8M+14.5%$95.2M+12.7%$106.3M+23.9%$99.9M+20.4%
Current Liabilities$72.2M+43.2%$59.6M+58.7%$55.4M+18.1%$62.0M+57.4%$50.4M+52.9%$37.6M+0.2%$46.9M+43.4%$39.4M+47.3%
Non-Current Liabilities$197.5M+250.7%$199.6M+246.2%$103.4M+74.2%$104.8M+73.0%$56.3M-6.5%$57.6M+22.6%$59.4M+11.8%$60.6M+7.6%
Long-Term Debt$196.2M+294.3%$196.6M+295.3%$99.7M+98.8%$99.6M+98.8%$49.8M+2.6%$49.7M+11.5%$50.1M+3.0%$50.1M+0.3%
Total Equity$253.8M+8.8%$276.0M-11.6%$245.5M-33.4%$245.0M+209.4%$233.3M+74.6%$312.3M+70.9%$368.6M+63.7%$79.2M-52.8%
Retained Earnings-$1.5B-36.9%-$1.4B-41.0%-$1.3B-41.0%-$1.2B-41.3%-$1.1B-39.9%-$997.4M-36.0%-$922.7M-36.4%-$856.3M-35.9%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.

SRRK Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SRRK quarterly cash flow statement
MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-Q
Operating Cash Flow-$70.3M+8.6%-$82.1M-4.4%-$75.5M-52.5%-$68.9M-31.4%-$76.9M-56.4%-$78.7M-58.0%-$49.5M-32.6%-$52.5M-62.5%
Depreciation & Amortization$297K-28.8%$335K-14.8%$425K+7.6%$423K-5.2%$417K-16.3%$393K-34.3%$395K-41.2%$446K-37.0%
Stock-Based Compensation$19.7M-19.5%$18.2M+36.0%N/A$18.3M+90.0%$24.4M+162.4%$13.4M+64.3%N/A$9.7M+34.0%
Capital Expenditures$1K-99.5%$68K-74.9%$32K+45.5%$84K+171.0%$215K+877.3%$271K+1078.3%$22K$31K
Free Cash Flow-$70.3M+8.9%-$82.2M-4.1%-$75.5M-52.5%-$69.0M-31.5%-$77.2M-56.8%-$78.9M-58.5%-$49.5M-32.6%-$52.5M-62.6%
Investing Cash Flow-$5.5M-106.4%-$5.3M-115.4%$39.0M+119.9%$59.7M+69.1%$85.5M+68.8%$34.6M+3.5%-$195.4M-677.5%$35.3M+516.7%
Financing Cash Flow$83.1M+1183.9%$193.8M+4548.3%$73.3M-78.8%$144.5M+86929.5%$6.5M+19718.2%$4.2M-36.1%$346.4M+258.8%$166K-40.7%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

SRRK Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SRRK quarterly financial ratios
MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-Q
Return on Equity-43.3%+3.9pp-38.2%-14.3ppN/A-41.7%+39.7pp-47.2%-3.4pp-23.9%+7.2ppN/A-81.4%-56.2pp
Return on Assets-21.0%+11.4pp-19.7%-1.4ppN/A-24.8%+11.2pp-32.4%-6.6pp-18.3%+2.9ppN/A-36.0%-19.1pp
Current Ratio7.02+0.7x8.64-1.6x6.95-2.7x6.30+2.4x6.33+0.3x10.25+3.7x9.61+0.8x3.88-4.7x
Debt-to-Equity0.77+0.6x0.71+0.6x0.41+0.3x0.41-0.2x0.21-0.1x0.16-0.1x0.14-0.1x0.63+0.3x
Asset TurnoverN/A0.00N/AN/AN/AN/AN/AN/A

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Scholar Rock Holding Corporation SRRK FY2025 $0 -$378.0M N/A $6.7B
Apellis Pharmaceuticals, Inc. APLS FY2025 $1.0B $22.4M 2.2% $5.3B 42/100
Immunovant, Inc. IMVT FY2026 N/A -$505.6M N/A $7.9B
Kymera Therapeutics, Inc. KYMR FY2025 $39.2M $311.4M N/A $9.7B 38/100
Soleno Therapeutics, Inc. SLNO FY2025 $190.4M $20.9M 11.0% $2.8B 59/100
Ultragenyx Pharmaceutical Inc. RARE FY2025 $673.0M -$575.0M -85.4% $1.4B 56/100

Frequently Asked Questions

What is Scholar Rock Holding Corporation's annual revenue?

Scholar Rock Holding Corporation (SRRK) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Scholar Rock Holding Corporation profitable?

No, Scholar Rock Holding Corporation (SRRK) reported a net income of -$378.0M in fiscal year 2025.

What is Scholar Rock Holding Corporation's earnings per share (EPS)?

Scholar Rock Holding Corporation (SRRK) reported diluted earnings per share of -$3.29 for fiscal year 2025. This represents a -33.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Scholar Rock Holding Corporation (SRRK) had EBITDA of -$383.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, Scholar Rock Holding Corporation (SRRK) had $323.5M in cash and equivalents against $99.7M in long-term debt.

Scholar Rock Holding Corporation (SRRK) has a return on equity of -154.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Scholar Rock Holding Corporation (SRRK) recorded an outflow of $300.6M in free cash flow during fiscal year 2025. This represents a -49.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Scholar Rock Holding Corporation (SRRK) recorded an outflow of $300.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Scholar Rock Holding Corporation (SRRK) had $404.3M in total assets as of fiscal year 2025, including both current and long-term assets.

Scholar Rock Holding Corporation (SRRK) invested $602K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Scholar Rock Holding Corporation (SRRK) invested $208.4M in research and development during fiscal year 2025.

Scholar Rock Holding Corporation (SRRK) had 115M shares outstanding as of fiscal year 2025.

Scholar Rock Holding Corporation (SRRK) had a current ratio of 6.95 as of fiscal year 2025, which is generally considered healthy.

Scholar Rock Holding Corporation (SRRK) had a debt-to-equity ratio of 0.41 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Scholar Rock Holding Corporation (SRRK) had a return on assets of -93.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Scholar Rock Holding Corporation (SRRK) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $6.7B as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Scholar Rock Holding Corporation (SRRK) has no price-to-sales ratio at the moment: revenue is not positive (FY2025). The market capitalization is $6.7B as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Scholar Rock Holding Corporation (SRRK) held $367.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $300.0M over that year. Dividing the one by the other, the reported balance equals about 15 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Scholar Rock Holding Corporation (SRRK) has an Altman Z-Score of 18.83, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Scholar Rock Holding Corporation (SRRK) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Scholar Rock Holding Corporation (SRRK) reported a net loss of $378.0M while operations used $300.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Scholar Rock Holding Corporation (SRRK) reported an operating loss of $384.6M against $6.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Back to top